Using aripiprazole to reduce antipsychotic-induced hyperprolactinemia: meta-analysis of currently available randomized controlled trials

Shanghai Archives of Psychiatry

Volumn 27, Issue 1, 2015, Pages 4-17

  Meng, Meiling ^a   Li, Wei ^a   Zhang, Shaowei ^a   Wang, Hongyan ^a   Sheng, Jianhua ^a   Wang, Jijun ^a   Li, Chunbo ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Aripiprazole; Hyperprolactinemia; Meta analysis; Randomized controlled trial

Indexed keywords

EID: 84929151470     PISSN: 10020829     EISSN: None     Source Type: Journal    
DOI: 10.11919/j.issn.1002-0829.215014     Document Type: Article

References (64)

1. Haddad PM, Wieck A. Antipsychotic-induced hyperpro-lactinaemia: mechanisms, clinical features and management. Drugs. 2004; 64(20): 2291-2314
2. Halbreich U, Kahn LS. Hyperprolactinemia and schizophrenia: mechanisms and clinical aspects. J Psychiatr Pract. 2003; 9(5): 344-353. doi: http://dx.doi.org/10.1097/00131746-200309000-00003
3. Melkersson K. Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients. J Clin Psychiatry. 2005; 66(6): 761-767
4. Johnsen E, Kroken RA, Abaza M, Olberg H, Jørgensen H. Antipsychotic-induced hyperprolactinemia: a cross-sectional survey. J Clin Psychopharmacol. 2008. 28(6): 686-690. doi: http://dx.doi.org/10.1097/JCP.0b013e31818ba5d8
5. Wang ZM, Xiang YT, Rong F, Correll CU, Ungvari GS, Wang Y, et al. Frequency of hyperprolactinemia and its associations with demographic and clinical characteristics and antipsychotic medications in psychiatric inpatients in China. Perspect Psychiatr Care. 2014; 50(4): 257-263. doi: http://dx.doi.org/10.1111/ppc.12050
6. Holt RI, Peveler RC. Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management. Clin Endocrinol (Oxf). 2011; 74(2): 141-147. doi: http://dx.doi.org/10.1111/j.1365-2265.2010.03814.x
7. Byerly M, Suppes T, Tran QV, Baker RA. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J Clin Psychopharmacol. 2007; 27(6): 639-661. doi: http://dx.doi.org/10.1097/jcp.0b013e31815ac4e5
8. Cookson J, Hodgson R, Wildgust HJ. Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis. J Psychopharmacol. 2012; 26(5 Suppl): 42-51. Epub 2012 Apr 2. doi: http://dx.doi.org/10.1177/0269881112442016
9. Kishimoto T, De Hert M, Carison HE, Manu P, Correll CU. Osteoporosis and fracture risk in people with schizophrenia. Curr Opin Psychiatry. 2012; 25(5): 415-429. doi: http://dx.doi.org/10.1097/YCO.0b013e328355e1ac
10. Krysiak R, Kedzia A, Okopien B. Unfavorable effects of hyperprolactinemia in autoimmune endocrine disorders. Neuro Endocrinol Lett. 2012; 33(3): 298-300
11. Inder WJ, Castle D. Antipsychotic-induced hyperpro-lactinaemia. Aust N Z J Psychiatry. 2011; 45(10): 830-837. doi: http://dx.doi.org/10.3109/00048674.2011.589044
12. Rainka MM, Capote HA, Ross CA, Gengo FM. Attenuation of risperidone-induced hyperprolactinemia with the addition of aripiprazole. J Clin Pharm Ther. 2009; 34(5): 595-598. doi: http://dx.doi.org/10.1111/j.1365-2710.2008.01009.x
13. Lin SK, Chen CK. Reversal of antipsychotic-induced hyper-prolactinemia, weight gain, and dyslipidemia by aripiprazole: A case report. J Clin Psychiatry. 2006; 67(8): 1307
14. Chen JX, Su YA, Wang SL, Bian QT, Liu YH, Wang N, et al. Aripiprazole treatment of risperidone-induced hyperprolactinemia. J Clin Psychiatry. 2009; 70(7): 1058-1059. doi: http://dx.doi.org/10.4088/JCP.08l04671
15. Wahl R, Ostroff R. Reversal of symptomatic hyperprolactinemia by aripiprazole. Am J Psychiatry. 2005; 162(8): 1542-1543. doi: http://dx.doi.org/10.1176/appi.ajp.162.8.1542-a
16. Mir A, Shivakumar K, Williamson RJ, McAllister V, O'Keane V, Aitchison KJ. Change in sexual dysfunction with aripiprazole: a switching or add-on study. J Psychopharmacol. 2008; 22(3): 244-253. doi: http://dx.doi.org/10.1177/0269881107082901
17. Lorenz RA, Weinstein B. Resolution of haloperidol-induced hyperprolactinemia with aripiprazole. J Clin Psychopharmacol. 2007; 27(5): 524-525. doi: http://dx.doi.org/10.1097/JCP.0b013e31814f4d5d
18. Shim JC, Shin JG, Kelly DL, Jung DU, Seo YS, Liu KH. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry. 2007; 164(9): 1404-1410. doi: http://dx.doi.org/10.1176/appi.ajp.2007.06071075
19. Kane JM, Correll CU, Goff DC, Kirkpatrick B, Marder SR, Vester-Blokland E, et al. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry. 2009; 70(10): 1348-1357. doi: http://dx.doi.org/10.4088/JCP.09m05154yel
20. Chen HZ, Niu FR, Qian MC, Yu BR, Shen XH, Yang SG, et al. [The effect of Aripiprazole plus risperidone on the level of hyperprolactinemia of male patients with schizophrenia]. Zhong Hua Jing Shen Ke Za Zhi. 2009; 42(4): 224-227. Chinese
21. Chen LJ, Zhuo ZM, Zhuang H. [A study of aripiprazole in sulpiride induced male hyperprolactinemia]. Lin Chuang Jing Shen Yi Xue Za Zhi. 2010; 20(5): 304-305. Chinese
22. Xie J. [Aripiprazole on the treatment of hyperprolactinemia for schizophrenia induced byamisulpride]. Qiqihaer Yi Xue Yuan Xue Bao. 2013; 34(16): 2350-2352. Chinese
23. Liang J, Yan J, Zhang XY. [Randomized, double-blind, placebo-controlled study of aripiprazole reducing the elevation of prolactin induced by paliperidone in the treatment of schizophrenia]. Zhongguo Xin Yao Za Zhi. 2014; 11: 1300-1303, 1310. Chinese
24. Xu LP, Ji JY, Shi H, Zhai FL, Zhang B, Shao YQ, et al. [A control study of aripiprazole in the treatment of hyperprolactinemia by antipsychotics]. Zhongguo Xing Wei Yi Xue Ke Xue. 2006; 15(18): 718-720. Chinese. doi: http://dx.doi.org/10.3760/cma.j.issn.1674-6554.2006.08.019
25. Liu ZB. [Study of lactation and amenorrhea induced by low-dose aripiprazole treatment with antipsychotics]. Sichuan Jing Shen Wei Sheng. 2009; 22(1): 46-47. Chinese
26. Sun J, Zhang W. [60 cases of hyperprolactinemia induced by small doses of aripiprazole treatment with risperidone]. Zhongguo Bao Jian Ying Yang. 2014; 24(4): 2242-2243. Chinese.
27. Chen JX, Zhang RZ, Li W, Liu YH, Jiang LY, Bian QT, et al. [Adjunctive treatment of risperidone-induced hyperprolactinemia with aripiprazole: a randomized, double-blind, placebo-controlled study]. Zhongguo Xin Yao Za Zhi. 2014; 7: 811-814. Chinese
28. Li X, Tang Y, Wang C. Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials. PLoS One. 2013; 8(8): e70179. doi: http://dx.doi.org/10.1371/journal.pone.0070179
29. Frances A, Pincus HA, First MB. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington: American Psychiatric association; 1994
30. World Health Organization. [ICD-10 Diagnostic Criteria of Classification of Mental and Behavioral Disorders. Translated by Liu P, Xu YX]. Beijing: People's Medical Publishing House; 1995. Chinese
31. Psychiatry branch of Chinese Medical Society. [CCMD-3 Chinese Classification and Diagnostic Criteria for Mental Disorders, 3rd edition]. Jinan: Shandong Science and Technology Press; 2001. Chinese
32. JPT CHH, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration. 2011
33. Guyatt GH, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336(7650): 924-926. doi: http://dx.doi.org/10.1136/bmj.39489.470347.AD
34. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health, DHEW Publ ADM; 1976. pp: 223-244
35. Hartling L, Hamm MP, Milne A, Vandermeer B, Santaguida PL, Ansari M, et al. Testing the risk of bias tool showed low reliability between individual reviewers and across consensus assessments of reviewer pairs. J Clin Epidemiol. 2013; 66(9): 973-981. doi: http://dx.doi.org/10.1016/j.jclinepi.2012.07.005
36. Li CB, He YL, Zhang MY. [The rational application of consistency test methods]. Shanghai Arch Psychiatry. 2000; 4: 228-230, 232. Chinese
37. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414): 557-560. doi: http://dx.doi.org/10.1136/bmj.327.7414.557
38. Zhang B, Wang L, Xu LP, Shi JA, Sun J. [Clinical study of aripiprazole treatment on hyperprolactinemia induced by perphenazine]. Shen Jing Ji Bing Yu Jing Shen Wei Sheng. 2008; 8(5): 375-376. Chinese
39. Ji JY, Song ZX, Xu LP, Sun J, Shi JA, Zhao HJ, Wang HL. [Aripiprazole in treatment of female schizophrenics with risperidone induced hyperprolactinemia]. Zhong Hua Jing Shen Ke Za Zhi. 2008; 41(3): 169-171. Chinese. doi: http://dx.doi.org/10.3321/j.issn:1006-7884.2008.03.011
40. Jin JF, Cao YQ, Xu LP, Song ZY, Shao YQ. [Clinical studies on improving hyperprolactinemia induced by chlorpromazine with small doses of aripiprazole]. Jing Shen Yi Xue Za Zhi. 2008; 21(6): 455-456. Chinese. doi: http://dx.doi.org/10.3969/j.issn.1009-7201.2008.06.022
41. Wang L, Zhang B, Xu LP, Shi JA, Shao YQ. [A clinical study on aripiprzole in the treatment of female hyperprolactinemia by haloperidol]. Zhongguo Jian Kang Xin Li Xue Za Zhi. 2009; 17(2): 194-195. Chinese
42. Song ZX, Chen Q, Xu LP, Cai ZK, Ji JY, Wang WH, et al. [70 cases of aripiprazole treatment on hyperprolactinemia induced by sulpiride]. Yi Yao Dao Bao. 2009; 28(4): 479-481. Chinese. doi: http://dx.doi.org/10.3870/yydb.2009.04.030
43. Liu L, Qi SG, Dong XH, Jiang DZ, Cui FW, Pan QH. [A placebo- controlled trial of adjunctive treatment with aripiprazole for risperidone-induced hyperprolactinemia]. Zhongguo Jian Kang Xin Li Xue Za Zhi. 2011; 19(11): 1288-1290. Chinese
44. Liu ZB, Cao B, Jiao F, Li DC, Chen HB, Liu W. [A control study of aripiprazole in the treatment for antipsychotics-induced hyperprolactinemia]. Zhongguo Yi Yuan Yao Xue Za Zhi. 2011; 31(10): 843-846. Chinese
45. Xun W, Zhang JL, Kang MX. [Improving of Combined aripiprazole treatment on weight gain and prolactin increased levels induced by olanzapine treatment on female patients with schizophrenia]. Sichuan Jing Shen Wei Sheng. 2011; 24(2): 98-100. Chinese. doi: http://dx.doi.org/10.3969/j.issn.1007-3256.2011.02.013
46. Xue L, Zhou LJ, Tan WZ, Zhou YF, Hu JW, Huang ZM. [Efficacy analysis of Aripiprazole treatment on hyperprolactinemia induced by risperidone in 68 male patients]. Jilin Yi Xue. 2012; 33(1): 107-108. Chinese. doi: http://dx.doi.org/10.3969/j.issn.1004-0412.2012.01.063
47. Zhou HS, Li B, Liu J, Wang HL. [The efficacy and safety of aripiprazole in the treatment of female hyperprolactinemia caused by risperidone]. Zhongguo Jian Kang Xin Li Xue Za Zhi. 2012; 20(8): 1129-1130. Chinese
48. Zhu JX, Yin JB. [Clinical case-control study of aripiprazole treatment on hyperprolactinemia induced by risperidone in female patients]. Zhongguo She Qu Yi Shi (Yi Xue Zhuan Ye). 2012; 14(1): 124-125. Chinese. doi: http://dx.doi.org/10.3969/j.issn.1007-614x.2012.01.115
49. Wu HL, Lin DD, Li Y, Xu YJ. [Influence of aripiprazole on hyperprolactinemia caused by antipsychotics in elderly patients with schizophrenia]. Lin Chuang Jing Shen Yi Xue Za Zhi. 2013; 23(4): 263-264. Chinese
50. Guo JH, Cao CA, Liao CP, Xu YM, Liu YY. [A control study on aripiprazole in the treatment of hyperprolactinaemaia by antipsychotics]. Zhongguo Jian Kang Xin Li Xue Za Zhi. 2013; 21(4): 487-489. Chinese
51. Pan JY, Wei YL. [Clinical observation of aripiprazole orally disintegrating tablets on weight gain and prolactin increase caused by risperidone and sulpiride]. You Jiang Yi Xue. 2014; 42(1): 48-50, 53. Chinese. doi: http://dx.doi.org/10.3969/j.issn.1003-1383.2014.01.014
52. Qiao, Y, Sheng JH, Li CB, Guo Q, Wen H, Zhu SY. [Add-on effects of low dose aripiprazole in resolving hyperprolactinemia induced by risperidone or paliperidone]. Unpublished Article, 2015. Chinese. (This study was registered on the China Clinical Trial Register (http://www.chictr.org/en/proj/search.aspx) on 8 January 2014. The protocol can be accessed by entering the registration number for the study (ChiCTR-TRC-14004186) on this website and the results of the study, that were used in this paper, are available by contacting the first author of the protocol.)
53. Lewis AO, Paul MR. Informant questionnaire for the positive and negative syndrome scale (IQ-PANSS). 1999. Muti-Health Systems Inc.
54. Lukoff D, Nuechterlein KH, Ventura J. Manual for the Expanded Brief Psychiatric Rating Scale. Schizophr Bull. 1986; 13: 594-602
55. Yokoi F, Gründer G, Biziere K, Stephane M, Dogan AS, Dannals RF, et al. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology. 2002; 27(2): 248-259. doi: http://dx.doi.org/10.1016/S0893-133X(02)00304-4
56. Duan DX, Cui GM. [The clinical observation and follow-up on Risperidone-induced hyperprolactinemia]. Shi Yong Yi Xue Za Zhi. 2010; 26(17): 3215-3216. Chinese. doi: http://dx.doi.org/10.3969/j.issn.1006-5725.2010.17.062
57. Wang ZW, Zhang SP, Zhou TX, Chen YD, Liu RS. [Effect of risperidone on life quality in schizophrenics: Meta-analysis]. Lin Chuang Jing Shen Yi Xue Za Zhi. 2004; 14(5): 270-272. Chinese
58. Shah SK. A comparative study of sexual dysfunction in schizophrenia patients taking aripiprazole versus risperidone. Kathmandu Univ Med J (KUMJ). 2013; 11(42): 121-125
59. Zhu ZQ, Zhang MY. [Progress of the study on the third generation antipsychotics aripiprazole]. Zhongguo Yi Yuan Yong Yao Ping Jia Yu Fen Xi. 2005; 5(2): 121-123. Chinese
60. Huang WW, Jiang DG. [New antipsychotic aripiprazole]. Shanghai Arch Psychiatry. 2003; 15(5): 307-308. Chinese. doi: http://dx.doi.org/10.3969/j.issn.1002-0829.2003.05.020
61. Shen YC. [Psychiatry]. Beijing: People's Medical Publishing House. 2009; pp: 528-529. Chinese
62. Prato GP, Pagliaro U, Buti J, Rotundo R, Newman MG. Evaluation of the literature: evidence assessment tools for clinicians. J Evid Based Dent Pract. 2013; 13(4): 130-141. doi: http://dx.doi.org/10.1016/j.jebdp.2013.08.001
63. Atkins D. Grading quality of evidence and strength of recommendations. BMJ. 2004; 328(7454): 1490. doi: http://dx.doi.org/10.1136/bmj.328.7454.1490
64. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med. 2001; 134: 663-694. doi: http://dx.doi.org/10.7326/0003-4819-134-8-200104170-00012